X

RPG Life Sciences Ltd Stock Analysis

Small Cap
Evaluated by 563 users | BSE: 532983 | NSE: RPGLIFE |
Pharmaceuticals & Drugs
RPG Life Sciences (RPGLS) is a pharmaceutical organization and was formerly known as Searle (India) Limited. It is a full spectrum world class, customer focussed, innovative pharmaceutical organisation. RPGLS started in 1968 as a joint venture with GD Searle, USA. In 1993, GD...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 13.96%4.25%6.65%6.28%1.59%8.16%13.59%8.27%6.79%17.85%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 187193222236242279294344330376
Y-o-Y Gr. Rt.-3.2%15%6.3%2.9%15.3%5.1%17.1%-4%13.8%
Adjusted EPS (Rs.) 7.520.372.224.20.286.7112.758.026.2819.63
Y-o-Y Gr. Rt.--95.1%500%89.2%-93.3%2296.4%90%-37.1%-21.7%212.6%
Book Value per Share (Rs.) 45.2544.8346.176.0575.6880.7888.8993.5897.05106.77
Adjusted Net Profit 12.40.63.770.511.121.113.310.432.5
Net Op. Cash Flow (Rs. Cr.) 14.415.612.3-5.6-232.87.314.745.850.2
Debt to Cash Flow from Ops 3.663.475.11-2.61-16.870.696.13.690.80.23
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
RPG Life Sciences Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 8.1%9.2%8.6%13.8%
Adjusted EPS 11.3%134%15.5%212.6%
Book Value per Share 107.16.310
Share Price 24.4% 12.5% 3.6% 100.9%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 17.860.834.886.880.378.5815.038.796.5919.26
Operating Profit Margin (%) 17.429.427.074.753.517.989.7910.7810.4515.98
Net Profit Margin (%) 6.660.321.652.950.193.977.183.863.158.64
Debt to Equity 0.710.730.830.120.270.170.30.350.230.07
Working Capital Days 134148146154150137123126136115
Cash Conversion Cycle 4313136524849555549
Entity Percentage Holding
Promoters 72.07%
Institutions 0.04%
Non-Institutions 27.89%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of RPG Life Sciences Ltd's performance infers:

RPG Life Sciences Ltd earnings have grown by 134%, whereas share price has appreciated 12.5% CAGR over the past five years, indicating the company's share price is likely undervalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of RPG Life Sciences Ltd share prices over the last 10 years. Here is what we found out:

RPG Life Sciences Ltd share price has appreciated 19.5% annually over the past ten years.

RPG Life Sciences (RPGLS) is a pharmaceutical organization and was formerly known as Searle (India) Limited. It is a full spectrum world class, customer focussed, innovative pharmaceutical organisation. RPGLS started in 1968 as a joint venture with GD Searle, USA. In 1993, GD Searle withdrew from India and sold its holdings to the RPG Group. The company’s name was changed to RPG Life Sciences Ltd effective April 1, 1999.This company belongs to RPG group

RPGLS was in

RPG Life Sciences (RPGLS) is a pharmaceutical organization and was formerly known as Searle (India) Limited. It is a full spectrum world class, customer focussed, innovative pharmaceutical organisation. RPGLS started in 1968 as a joint venture with GD Searle, USA. In 1993, GD Searle withdrew from India and sold its holdings to the RPG Group. The company’s name was changed to RPG Life Sciences Ltd effective April 1, 1999.This company belongs to RPG group

RPGLS was in the business of pharmaceuticals and agrochemicals. It divested the agrochemicals business in the year 2001, as per the strategic decision to focus on pharmaceuticals, fermentation and biotechnology. It develops, manufactures and markets, for national and international markets, a broad range of branded formulations, generics and bulk drugs developed through fermentation and chemical synthesis routes. RPG Life Sciences has research and development facilities that conform to international standards. It has Biotech R&D, API R&D and Formulations R&D. Each of these areas have their respective manufacturing facilities RPGLS employs 750 people. It is a multi-location pharmaceutical manufacturing company with four locations. The manufacturing unit at Thane produces Active Pharmaceuticals Ingredients (also called as bulk drugs) and is ISO 9001 certified and has Therapeutic Goods Administration (TGA), Australia, and approval for three of its major products namely Diphenoxylate Hydrochloride, Haloperidol and Propanthelene Bromide.

The Formulation Plant at Ankleshwar GIDC is ISO 9002 and ISO14001 certified and manufactures pharmaceuticals formulations for domestic as well as for exports. The site also has MHRA (Medicines and Healthcare products Regulatory Agency, UK) approved plant for catering to its global generic business. The second plant at Ankleshwar makes API through the fermentation route to cater to the biotech business.

RPGLS is present in the domestic as well as the international markets. It exports its products primarily to Europe, Latin America, Africa, Australia, CIS Nations and South East Asia.

Major Activities of the Company:

  • Manufacturing and marketing of bulk drugs (synthetic Active Pharmaceutical Ingredients) & formulations internationally [SBU- I],
  • Pharmaceutical formulations & domestic marketing [SBU – II] and Fermentation & biotechnology [SBU – III].

Company’s Patnership:

It is represented in over thirty countries through strategic partnerships and joint ventures.

  • Dossiers/DMF Europe, Canada
  • Artificial Sweetner-UK
  • NSAID-Europe
  •  Formulations - Asia, Canada, Europe.

Achievements:

  • 8 processes patented granted,both in India and overseas
  • First to manufacture Cyclosporin, Daunarubicin, doxorubican and epirubicin in India
  • One of the two manufacturers of Vitamin B12 in India
  • R&D approved  by Department of Science & Technology, Government of India.
  • Only manufacturer of Spironolactone, by the fermentation route, in India.
  • Marketing APIs and formulations catering to all key therapeutic areas across the world.
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback